Lipocalin-2, glucose metabolism and chronic low-grade systemic inflammation in Chinese people

Table 3 The risk of impaired glucose regulation and type 2 diabetes associated with a 10 ng/ml increase in serum lipocalin-2

Model	IGR (n = 984)	p value^a	impaired glucose regulation and type 2 diabetes (n = 1376)	p value^b
Model 1	1.48 (1.34-1.87)	< 0.001	1.55 (1.43-1.97)	< 0.001
Model 2	1.43 (1.31-1.75)	< 0.001	1.47 (1.38-1.85)	< 0.001
Model 3	1.40 (1.31-1.81)	< 0.001	1.41 (1.29-1.81)	< 0.001
Model 4	1.35 1.24-1.65)	< 0.001	1.38 (1.25-1.81)	< 0.001
Model 5	1.30 (1.23-1.62)	0.009	1.31 (1.21-1.69)	< 0.001

Values are ORs (95% CI)
Model 1: Unadjusted. Model 2: Adjusted for age, sex, smoking (yes/no), alcohol drinking (yes/no), family history of diabetes (yes/no). Model 3: Further adjusted for HOMA-IR, BMI, waist/hip ratio and adiponectin. Model 4: Further adjusted for serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol. Model 5: Further adjusted for inflammatory factors (CRP and CXCL5). ^aFor the risk of IGR, we defined subjects with normal glucose regulation as 0 (n = 1143) and IGR as 1 (n = 984), excluding type 2 diabetes (n = 392) from the analysis. ^bFor the risk of combined IGR and type 2 diabetes, we defined subjects with normal glucose regulation as 0 (n = 1143) and combined IGR and type 2 diabetes as 1 (n = 1376).

ISSN: 1475-2840